Login

Boston Walk for PKD

Goldfinch Bio

Goldfinch Bio is a research-stage biotechnology company focused on discovering and developing precision medicines for patients with kidney disease. 

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common single gene diseases, affecting more than 600,000 people in the US and 12 million worldwide. The disease is passed on from parent to child, with each child of an affected parent having a 1-in-2 chance of inheriting the disorder, which does not skip generations.

ADPKD patients develop fluid filled cysts in both kidneys that increase in number and size over time, culminating in end stage kidney disease in half of affected individuals by middle age. ADPKD commonly causes liver cysts which arise from bile ducts and can sometimes grow large enough to cause symptoms as well. In the United States, 1 in 20 individuals either on dialysis or with a kidney transplant has ADPKD.

There are no FDA approved therapies specifically targeting ADPKD and no means by which to alter the course of the disease.

Goldfinch is leveraging scientific discoveries based on the known genes that cause ADPKD to discover treatments to alter the course of ADPKD and drastically improve the lives of patients suffering from this chronic and debilitating disease.

View More

PKD Foundation

We are the only organization in the U.S. solely dedicated to finding treatments and a cure for PKD to improve the lives of those it affects.

Our vision is that one day no one will suffer the full effects of PKD.

Our home: 1001 E. 101st Terrace, Suite 220, Kansas City, MO, 64131

PKD Foundation is a 501 (c)(3), 509 (a)(1) public charity.
Federal tax ID: 43-1266906

financials | media | careers | privacy policy | terms and conditions
2017, PKD Foundation